Publicacions científiques

ESTEVE - Publicacions científiques

A ESTEVE ens esforcem per difondre els descobriments en revistes científiques d'alt nivel, revisades per parells.

A continuació trobaràs el llistat amb els últims treballs publicats.


Co-crystals as a new approach to multimodal analgesia and the treatment of pain. Journal of pain research. 2019, 12: 2679-2689

Sigma-1 receptor inhibition reduces neuropathic pain induced by partial sciatic nerve transection in mice by opioid-dependent and -independent mechanisms. Frontiers in pharmacology. 2019, 10(art.613): 1-16

Blockade of the sigma-1 receptor relieves cognitive and emotional impairments associated to chronic osteoarthritis pain. Frontiers in pharmacology. 2019, 10(Art.468): 1-15

Repeated sigma-1 receptor antagonist MR309 administration modulates central neuropathic pain development after spinal cord injury in mice. Frontiers in pharmacology. 2019, 10(Art.222): 1-14

Pharmacokinetics of tramadol and celecoxib in Japanese and Caucasian subjects following administration of co-crystal of tramadol-celecoxib (CTC): A randomised, open-label study. European journal of drug metabolism and pharmacokinetics. 2019, 44(1): 63-75

Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert opinion on investigational drugs. 2019, 28(5): 399-409

Patrones de prescripcion de farmacos antihiperglucemiantes en pacientes ancianos en Espana: un estudio transversal nacional = Prescription patterns of antihyperglycemic drugs in elderly patients in Spain: A national cross-sectional study. Revista clínica española. 2019, Epub ahead of print: 1-7

Synthesis and structure-affinity relationships of spirocyclic benzopyrans with exocyclic amino moiety. Journal of medicinal chemistry. 2019, 62(8): 4204-4217

Modulation by Sigma-1 Receptor of Morphine Analgesia and Tolerance: Nociceptive Pain, Tactile Allodynia and Grip Strength Deficits During Joint Inflammation. Frontiers in pharmacology. 2019, 10(art.136): 1-16

May a sigma-1 antagonist improve neuropathic signs induced by cisplatin and vincristine in rats? European journal of pain. 2019, 23(3): 603-620

A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset. Frontiers in pharmacology. 2019, 10(Art.519): 1-16

Differential Solution Behavior of the New API-API Co-Crystal of Tramadol-Celecoxib (CTC) versus Its Constituents and Their Combination. Crystal growth and design. 2019, Epub ahead of print: 1-11

Trends in sigma-1 receptor research: a 25-year bibliometric analysis. Frontiers in pharmacology. 2019, 10(Art.564): 1-17

Influence of the acid-base ionization of drugs in their retention in reversed-phase liquid chromatography. Analytica chimica acta. 2019, 200-211

Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and 1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity. European journal of medicinal chemistry. 2019, 177: 47-62

Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists. Journal of labelled compounds and radiopharmaceuticals. 2019, Epub ahead of print: 1-68

Supraspinal and peripheral, but not intrathecal, 1R blockade by S1RA enhances morphine antinociception. Frontiers in pharmacology. 2019, 10(art.422): 1-13

Commentary on the "Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial". Implications for cardiovascular safety. Journal of cardiology and cardiovascular sciences. 2019, 3(1): 1-3

ESTEVE - Publicacions científiques